Stock Fundamentals

AI Research Report

Generate a comprehensive financial analysis report powered by AI

ELAN.US Logo

ELAN.US - Current Price

$23.91

Company Information

Company Name
Elanco Animal Health
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Exchange
NYSE
ISIN: US28414H1032
CIK: 0001739104
CUSIP: 28414H103
Currency: USD
Full Time Employees: 9,000
Phone: 877 352 6261
Fiscal Year End: December
IPO Date: Sep 20, 2018
Description:

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. It offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio, Credelio Cat, Credelio Plus, Interceptor Plus, Doncit, Drontal, Drontal Plus, and Trifexis trademarks; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. The company also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, it offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, the company offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and TruCan trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. It sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Address:

2500 Innovation Way, Greenfield, IN, United States, 46140

Directors & Officers

Name Title Year Born
Mr. Jeffrey N. Simmons President, CEO & Director 1967
Dr. Ramiro Martin Cabral Executive VP & President of Elanco International 1972
Dr. Ellen de Brabander Ph.D. Executive Vice President of Research, Development & Regulatory Affairs 1963
Mr. Timothy J. Bettington Executive Vice President of Corporate Strategy & Market Development 1974
Mr. Robert M. VanHimbergen Executive VP & CFO 1976
Mr. James M. Meer Senior VP & Chief Accounting Officer 1970
Mr. Chris Keeley Senior VP & Chief Information Officer NA
Mr. David S. Kinard Executive Vice President of Human Resources, Corporate Communications & Administration 1967
Ms. Tiffany Ann Kanaga VP of Investor Relations & ESG NA
Ms. Shiv O'Neill Executive Vice President, General Counsel & Corporate Secretary 1975

Shares Statistics

Shares Outstanding: 496.86M
Shares Float: 492.88M
% Insiders: 107.20%
% Institutions: 11,642.70%
Short % Float: 5.78%

Valuation Metrics

Enterprise Value: $15.38B
Trailing P/E: 341.00
Forward P/E: 22.73

Financial Highlights

Market Cap: $11.86B
EBITDA: $882.00M
P/E Ratio: $341.00
PEG Ratio: $4.13
Book Value: $13.58
Earnings/Share: $0.07
Profit Margin: 0.78%
Operating Margin: 2.38%
ROA (TTM): 1.15%
ROE (TTM): 0.54%
Revenue (TTM): $4.59B
Revenue/Share (TTM): $9.26
Earnings Growth (YOY): 116.70%
Revenue Growth (YOY): 10.40%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income

Operating Expenses

Balance Sheet Overview

Earnings Per Share (EPS)

Earnings History

Date EPS Actual EPS Estimate Difference Surprise %
Dec 31, 2025 0.00 0.12 N/A -10,000.00%
Sep 30, 2025 0.19 0.13 N/A 4,615.38%
Jun 30, 2025 0.26 0.20 N/A 3,000.00%
Mar 31, 2025 0.37 0.30 N/A 2,155.06%
Dec 31, 2024 0.14 0.15 N/A -578.73%
Sep 30, 2024 0.13 0.12 N/A 833.33%
Jun 30, 2024 0.30 0.24 N/A 2,500.00%
Mar 31, 2024 0.34 0.26 N/A 3,076.92%
Dec 31, 2023 0.08 0.11 N/A -2,727.27%
Sep 30, 2023 0.18 0.12 N/A 5,000.00%
Jun 30, 2023 0.18 0.05 N/A 26,000.00%
Mar 31, 2023 0.45 0.29 N/A 5,517.24%
Dec 31, 2022 0.19 0.13 N/A 4,615.38%
Sep 30, 2022 0.20 0.16 N/A 2,500.00%
Jun 30, 2022 0.36 0.25 N/A 4,400.00%
Mar 31, 2022 0.36 0.35 N/A 285.71%
Dec 31, 2021 0.21 0.17 N/A 2,352.94%
Sep 30, 2021 0.19 0.17 N/A 1,176.47%
Jun 30, 2021 0.28 0.26 N/A 769.23%
Mar 31, 2021 0.37 0.23 N/A 6,086.96%
Dec 31, 2020 0.12 0.09 N/A 3,333.33%
Sep 30, 2020 0.13 0.12 N/A 833.33%
Jun 30, 2020 0.09 0.06 N/A 5,000.00%
Mar 31, 2020 0.13 0.24 N/A -4,583.33%
Dec 31, 2019 0.23 0.23 N/A 0.00%
Sep 30, 2019 0.30 0.26 N/A 1,538.46%
Jun 30, 2019 0.28 0.26 N/A 769.23%
Mar 31, 2019 0.25 0.23 N/A 869.57%
Dec 31, 2018 0.29 0.28 N/A 357.14%
Sep 30, 2018 0.29 0.25 N/A 1,600.00%
Jun 30, 2018 -0.97 0.00 N/A N/A

Balance Sheet (Yearly)

Date Cash Total Debt Total Assets Total Liabilities Total Equity
2024-12-31 $468.00M $N/A $12.61B $6.52B $6.10B
2023-12-31 $352.00M $N/A $14.36B $8.14B $6.22B
2022-12-31 $345.00M $N/A $15.49B $8.20B $7.29B
2021-12-31 $638.00M $N/A $16.48B $8.97B $7.51B
2020-12-31 $495.00M $N/A $17.69B $9.22B $8.48B
2019-12-31 $334.00M $N/A $8.99B $3.44B $5.55B
2018-12-31 $474.80M $N/A $8.96B $3.76B $5.20B
2017-12-31 $323.40M $N/A $8.94B $1.15B $7.79B
2016-12-31 $258.80M $N/A $8.10B $1.07B $7.03B
2015-12-31 $N/A $N/A $N/A $N/A $N/A

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Sep 23, 2025 N/A N/A N/A N/A N/A N/A
Sep 22, 2025 N/A N/A N/A N/A N/A N/A
Aug 27, 2025 N/A N/A N/A N/A N/A N/A
Jun 26, 2025 N/A N/A N/A N/A N/A N/A
Jun 10, 2025 N/A N/A N/A N/A N/A N/A
May 12, 2025 N/A N/A N/A N/A N/A N/A
May 08, 2025 N/A N/A N/A N/A N/A N/A
Apr 10, 2025 N/A N/A N/A N/A N/A N/A
Mar 11, 2025 N/A N/A N/A N/A N/A N/A
Mar 07, 2025 N/A N/A N/A N/A N/A N/A

Watchlist

0

No stocks in watchlist